Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39


LSD1/KDM1A, a Gate-Keeper of Cancer Stemness and a Promising Therapeutic Target.

Karakaidos P, Verigos J, Magklara A.

Cancers (Basel). 2019 Nov 20;11(12). pii: E1821. doi: 10.3390/cancers11121821. Review.


The Histone Demethylase LSD1/ΚDM1A Mediates Chemoresistance in Breast Cancer via Regulation of a Stem Cell Program.

Verigos J, Karakaidos P, Kordias D, Papoudou-Bai A, Evangelou Z, Harissis HV, Klinakis A, Magklara A.

Cancers (Basel). 2019 Oct 17;11(10). pii: E1585. doi: 10.3390/cancers11101585.


Clinical Application of Next-Generation Sequencing as A Liquid Biopsy Technique in Advanced Colorectal Cancer: A Trick or A Treat?

Kastrisiou M, Zarkavelis G, Pentheroudakis G, Magklara A.

Cancers (Basel). 2019 Oct 16;11(10). pii: E1573. doi: 10.3390/cancers11101573. Review.


The Basis for Strain-Dependent Rat Aldehyde Dehydrogenase 1A7 (ALDH1A7) Gene Expression.

Touloupi K, Küblbeck J, Magklara A, Molnár F, Reinisalo M, Konstandi M, Honkakoski P, Pappas P.

Mol Pharmacol. 2019 Nov;96(5):655-663. doi: 10.1124/mol.119.117424. Epub 2019 Oct 1.


Soft X-Ray Tomography Reveals Gradual Chromatin Compaction and Reorganization during Neurogenesis In Vivo.

Le Gros MA, Clowney EJ, Magklara A, Yen A, Markenscoff-Papadimitriou E, Colquitt B, Myllys M, Kellis M, Lomvardas S, Larabell CA.

Cell Rep. 2016 Nov 15;17(8):2125-2136. doi: 10.1016/j.celrep.2016.10.060.


Revealing the Complexity of Breast Cancer by Next Generation Sequencing.

Verigos J, Magklara A.

Cancers (Basel). 2015 Nov 6;7(4):2183-200. doi: 10.3390/cancers7040885. Review.


Heterochromatin-mediated gene silencing facilitates the diversification of olfactory neurons.

Lyons DB, Magklara A, Goh T, Sampath SC, Schaefer A, Schotta G, Lomvardas S.

Cell Rep. 2014 Nov 6;9(3):884-92. doi: 10.1016/j.celrep.2014.10.001. Epub 2014 Oct 30.


Deep sequencing reveals new aspects of progesterone receptor signaling in breast cancer cells.

Kougioumtzi A, Tsaparas P, Magklara A.

PLoS One. 2014 Jun 4;9(6):e98404. doi: 10.1371/journal.pone.0098404. eCollection 2014.


Stochastic gene expression in mammals: lessons from olfaction.

Magklara A, Lomvardas S.

Trends Cell Biol. 2013 Sep;23(9):449-56. doi: 10.1016/j.tcb.2013.04.005. Epub 2013 May 18. Review.


Neurons expressing trace amine-associated receptors project to discrete glomeruli and constitute an olfactory subsystem.

Johnson MA, Tsai L, Roy DS, Valenzuela DH, Mosley C, Magklara A, Lomvardas S, Liberles SD, Barnea G.

Proc Natl Acad Sci U S A. 2012 Aug 14;109(33):13410-5. doi: 10.1073/pnas.1206724109. Epub 2012 Jul 26.


High-throughput mapping of the promoters of the mouse olfactory receptor genes reveals a new type of mammalian promoter and provides insight into olfactory receptor gene regulation.

Clowney EJ, Magklara A, Colquitt BM, Pathak N, Lane RP, Lomvardas S.

Genome Res. 2011 Aug;21(8):1249-59. doi: 10.1101/gr.120162.110. Epub 2011 Jun 24.


An epigenetic signature for monoallelic olfactory receptor expression.

Magklara A, Yen A, Colquitt BM, Clowney EJ, Allen W, Markenscoff-Papadimitriou E, Evans ZA, Kheradpour P, Mountoufaris G, Carey C, Barnea G, Kellis M, Lomvardas S.

Cell. 2011 May 13;145(4):555-70. doi: 10.1016/j.cell.2011.03.040. Epub 2011 Apr 28.


HDAC activity is required for efficient core promoter function at the mouse mammary tumor virus promoter.

Lee SC, Magklara A, Smith CL.

J Biomed Biotechnol. 2011;2011:416905. doi: 10.1155/2011/416905. Epub 2010 Dec 26.


A composite intronic element directs dynamic binding of the progesterone receptor and GATA-2.

Magklara A, Smith CL.

Mol Endocrinol. 2009 Jan;23(1):61-73. doi: 10.1210/me.2008-0028. Epub 2008 Nov 26.


Human tissue kallikreins: from gene structure to function and clinical applications.

Yousef GM, Obiezu CV, Luo LY, Magklara A, Borgoño CA, Kishi T, Memari N, Michael lP, Sidiropoulos M, Kurlender L, Economopolou K, Kapadia C, Komatsu N, Petraki C, Elliott M, Scorilas A, Katsaros D, Levesque MA, Diamandis EP.

Adv Clin Chem. 2005;39:11-79. Review. No abstract available.


Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression.

Michael IP, Sotiropoulou G, Pampalakis G, Magklara A, Ghosh M, Wasney G, Diamandis EP.

J Biol Chem. 2005 Apr 15;280(15):14628-35. Epub 2005 Feb 15.


Association of kallikrein expression in nipple aspirate fluid with breast cancer risk.

Sauter ER, Lininger J, Magklara A, Hewett JE, Diamandis EP.

Int J Cancer. 2004 Feb 10;108(4):588-91.


Complex formation between human kallikrein 13 and serum protease inhibitors.

Kapadia C, Yousef GM, Mellati AA, Magklara A, Wasney GA, Diamandis EP.

Clin Chim Acta. 2004 Jan;339(1-2):157-67.


Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors.

Magklara A, Mellati AA, Wasney GA, Little SP, Sotiropoulou G, Becker GW, Diamandis EP.

Biochem Biophys Res Commun. 2003 Aug 8;307(4):948-55.


The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer.

Yousef GM, Scorilas A, Magklara A, Memari N, Ponzone R, Sismondi P, Biglia N, Abd Ellatif M, Diamandis EP.

Br J Cancer. 2002 Nov 18;87(11):1294-300.


Ethnic variation in kallikrein expression in nipple aspirate fluid.

Sauter ER, Welch T, Magklara A, Klein G, Diamandis EP.

Int J Cancer. 2002 Aug 20;100(6):678-82.


The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer.

Magklara A, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Danese S, Diamandis EP.

Clin Cancer Res. 2001 Apr;7(4):806-11.


Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies.

Yousef GM, Magklara A, Chang A, Jung K, Katsaros D, Diamandis EP.

Cancer Res. 2001 Apr 15;61(8):3425-31.


Prostate-specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome.

Obiezu CV, Scorilas A, Magklara A, Thornton MH, Wang CY, Stanczyk FZ, Diamandis EP.

J Clin Endocrinol Metab. 2001 Apr;86(4):1558-61.


Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue.

Magklara A, Scorilas A, Stephan C, Kristiansen GO, Hauptmann S, Jung K, Diamandis EP.

Urology. 2000 Sep 1;56(3):527-32.


Expression of prostate-specific antigen and human glandular kallikrein 2 in the thyroid gland.

Magklara A, Cheung CC, Asa SL, Diamandis EP.

Clin Chim Acta. 2000 Oct;300(1-2):171-80.


Is ICI 182,780 an antiprogestin in addition to being an antiestrogen?

Rosenberg Zand RS, Grass L, Magklara A, Jenkins DJ, Diamandis EP.

Breast Cancer Res Treat. 2000 Mar;60(1):1-8.


Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen.

Nam RK, Diamandis EP, Toi A, Trachtenberg J, Magklara A, Scorilas A, Papnastasiou PA, Jewett MA, Narod SA.

J Clin Oncol. 2000 Mar;18(5):1036-42.


Dramatic suppression of plasma and urinary prostate specific antigen and human glandular kallikrein by antiandrogens in male-to-female transsexuals.

Obiezu CV, Giltay EJ, Magklara A, Scorilas A, Gooren L, Yu H, Diamandis EP.

J Urol. 2000 Mar;163(3):802-5.


The new human kallikrein gene family: implications in carcinogenesis.

Diamandis EP, Yousef GM, Luo LY, Magklara A, Obiezu CV.

Trends Endocrinol Metab. 2000 Mar;11(2):54-60. Review.


Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions.

Black MH, Magklara A, Obiezu C, Levesque MA, Sutherland DJ, Tindall DJ, Young CY, Sauter ER, Diamandis EP.

Br J Cancer. 2000 Jan;82(2):361-7.


Human glandular kallikrein in breast milk, amniotic fluid, and breast cyst fluid.

Magklara A, Scorilas A, López-Otín C, Vizoso F, Ruibal A, Diamandis EP.

Clin Chem. 1999 Oct;45(10):1774-80.


Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen.

Black MH, Magklara A, Obiezu CV, Melegos DN, Diamandis EP.

Clin Chem. 1999 Jun;45(6 Pt 1):790-9.

Supplemental Content

Loading ...
Support Center